Commercial OpportunityConsidering the ongoing stimulant shortages and that CTx-1301 only requires one daily dose, the commercial opportunity for Cingulate is considered attractive.
Regulatory ProgressThe FDA accepted Cingulate's NDA application for CTx-1301, indicating a significant step forward for the company's ADHD treatment.
Strategic PartnershipCingulate's partnership with Indegene, a company with over 20 years of experience, provides extensive services and AI-driven analytics to support a successful product launch.